R9Q Stock Overview Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Recce Pharmaceuticals Ltd Competitors Price History & Performance
Summary of share price highs, lows and changes for Recce Pharmaceuticals Historical stock prices Current Share Price AU$0.24 52 Week High AU$0.38 52 Week Low AU$0.23 Beta 1.04 1 Month Change -7.81% 3 Month Change -9.92% 1 Year Change -16.90% 3 Year Change -67.89% 5 Year Change n/a Change since IPO -27.14%
Recent News & Updates
Recce Pharmaceuticals Ltd Doses All Patients in Phase II Trial of Recce®? 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections Jan 22
Recce Pharmaceuticals Ltd Receives Approval from Indonesia's Drug and Food Authority for Registrational Phase 3 Trial of Recce®? 327 Topical Gel in Diabetic Foot Infections Dec 11
Recce Pharmaceuticals Ltd Receives Ethics Approval in Indonesia to Commence Registrational Phase 3 Trial of Recce®?327 Topical Gel in Diabetic Foot Infections Nov 12
Recce Pharmaceuticals Advances Patient Dosing to Final Stages in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections Nov 06
Recce Pharmaceuticals Announces Recruitment Passes Halfway in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections Oct 10
Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 06, 2024 Sep 16 See more updates
Recce Pharmaceuticals Ltd Doses All Patients in Phase II Trial of Recce®? 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections Jan 22
Recce Pharmaceuticals Ltd Receives Approval from Indonesia's Drug and Food Authority for Registrational Phase 3 Trial of Recce®? 327 Topical Gel in Diabetic Foot Infections Dec 11
Recce Pharmaceuticals Ltd Receives Ethics Approval in Indonesia to Commence Registrational Phase 3 Trial of Recce®?327 Topical Gel in Diabetic Foot Infections Nov 12
Recce Pharmaceuticals Advances Patient Dosing to Final Stages in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections Nov 06
Recce Pharmaceuticals Announces Recruitment Passes Halfway in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections Oct 10
Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 06, 2024 Sep 16
New major risk - Revenue and earnings growth Jul 16
Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter Baumannii Jul 10 Recce Pharmaceuticals Ltd has filed a Follow-on Equity Offering in the amount of AUD 2 million.
Recce Pharmaceuticals Reports Positive Data from Phase I/Ii Urinary Tract Infection (Uti) / Urosepsis Rapid Infusion Trial of Recce® 327 Jul 03
Recce Pharmaceuticals Ltd. Receives Ethics Approval to Broaden RECCE 327 Gel Trials Across All Topical Bacterial Skin Infections Jun 25
Recce Pharmaceuticals Announces Addition of RECCE® 327 to the World Health Organization’S List of Antibacterial Products in Clinical Development Jun 20
Recce Pharmaceuticals Ltd Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial May 18
Recce Pharmaceuticals Reports Positive Preclinical Data of Recce® 327 in Lung Infection Pilot Study May 15
Recce Pharmaceuticals Ltd Receives New Patent in China for RECCE Anti-Infectives from China National Intellectual Property Administration May 09
New major risk - Revenue and earnings growth May 08
Recce Pharmaceuticals Ltd. Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis Apr 30
Recce Pharmaceuticals Ltd. Completes 5,000 RECCE 327 Doses Week Under Good Manufacturing Practice Apr 17
Recce Pharmaceuticals Ltd Receives New Patent in Israel for Recce Anti-Infectives Apr 05
New major risk - Revenue and earnings growth Mar 27
Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of Recce® 327 for Urinary Tract Infections and Urosepsis Mar 20
Recce Pharmaceuticals Ltd Doses Next Cohort in Phase I/II Trial of RECCE 327 for Urinary Tract Infections and Urosepsis Mar 14
New major risk - Share price stability Mar 13
Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of RECCE 327 for the Treatment of Diabetic Foot Infections Jan 23
Recce Pharmaceuticals Receives Ausindustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Program Dec 20
Recce Pharmaceuticals Ltd Reports Positive Preclinical Data of RECCE 327 Against Gonorrhoeae Dec 19
Recce Pharmaceuticals Limited Announces Canadian Patent Granted for Recce® Anti-Infectives Nov 23
Recce Pharmaceuticals Ltd Completes Dosing First Subjects at 15-Minute Infusion Rate in a Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis Nov 10
Recce Pharmaceuticals Ltd Announces Safety Committee Approves Faster Infusion Rate in Phase I/Ii Trial of Recce® 327 for Urinary Tract Infections and Urosepsis Oct 26 Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 3.022261 million. Oct 06
Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 3.022261 million. Oct 05
Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.715261 million. Sep 29
Recce Pharmaceuticals Completes Dosing in Phase I/II Clinical Trial of Recce® 327 for Urinary Tract Infections Sep 27
Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 8 million. Sep 20 Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 8 million.
Recce Pharmaceuticals Ltd Provides Additional Positive Update on Patients Treated Under "Special Access Scheme" Sep 02
New minor risk - Financial data availability Aug 30
Recce Pharmaceuticals Ltd Announces Safety Committee Approves Next Dose of Recce®? 327 At 3,000Mg in Phase I/Iiuti/Urosepsis Rapid Infusion Clinical Trial Aug 30
Recce Pharmaceuticals Ltd Doses Patients in Phase I/II Clinical Trial of Recce 327 for Diabetic Foot Infections Aug 25
Recce Pharmaceuticals Ltd. Completes Stage 1 Data Analysis of Phase I/II Clinical Trial for the Treatment of Burn Wound Infections Aug 24
Recce Pharmaceuticals Ltd Provides Positive Update on Patients Treated with RECCE®? 327 Under "Special Access Scheme" Aug 11
New major risk - Share price stability Aug 09
Recce Pharmaceuticals Completes First Cohort Dosing of Phase l/ll UTI Rapid Infusion Clinical Trial at Scientia Clinical Research Aug 02
Recce Pharmaceuticals Achieves Positive Phase I Clinical Trial Data of RECCE(R) 327 as an Intravenous Infusion Formulation Jul 23
Recce Pharmaceuticals Limited Announces First Cohort Dosed in Recce®? 327 Rapid Infusion Phase I/II Urinary Tract Infection (UTI) Clinical Trial Jul 12
CEO, MD & Executive Director recently bought €190k worth of stock Jun 29
Recce Pharmaceuticals to Be Granted Anti-Viral Patent in Australia for RECCE® Anti-Infectives Jan 12
Recce Pharmaceuticals Limited Announces Australian Patent Office Issued Notification of Intent to Grant Recce's Patent Family 3 Jan 10
Recce Pharmaceuticals Ltd Receives Ethics Approval to Start Phase 1/2 Study Evaluating RECCE(R) 327 in Patients with Diabetic Foot Infections Dec 13
Recce Pharmaceuticals Ltd Receives Ethics Approval to Start Phase I/II Diabetic Foot Ulcer Study Dec 09
Less than half of directors are independent Nov 17 Recce Pharmaceuticals Ltd Provides RECCE 327 SARS-CoV-2 Study Update Oct 19
Recce Pharmaceuticals Ltd Provides RECCE 327 SARS-CoV-2 Study Update Oct 18
Recce Pharmaceuticals Announces Expansion and Acceleration of Clinical Programs Sep 27
Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 14, 2022 Sep 21
Recce Pharmaceuticals Appoints Alistair McKeough to Its Board of Directors and Maggie Niewidok as Company Secretary Sep 08
Recce Announces Management Changes Sep 01
Recce Pharmaceuticals Ltd Reports Positive Safety Data from Seventh Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327 Aug 22
Recce Pharmaceuticals Ltd announces Positive Safety Data from Fifth Cohort of Phase I Clinical Trial of RECCE 327 and Initiates Sixth Cohort At 4,000Mg May 20
Less than half of directors are independent Apr 27
Recce Pharmaceuticals Ltd Announces Anti-Viral Patent Granted in Hong Kong Apr 12 Recce Pharmaceuticals Ltd Announces Safety Committee Clears Next Dose in Phase I Study of Recce® 327 Mar 10
Recce Pharmaceuticals Ltd Announces Positive Safety Data from Second Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327 Jan 20
Recce Pharmaceuticals Ltd Announces Patients to be Dosed in a Phase I Intravenous Clinical Trial of RECCE® 327 Dec 16
Anti-Viral Patent Grants in USA for Recce Pharmaceuticals Ltd's RECCE Anti-Infectives Jul 24
Chinese Patent Office Grants Anti-Viral Patent to Recce Pharmaceuticals Ltd Jul 20
Board Member recently sold €113k worth of stock Jun 23
Recce Pharmaceuticals Ltd. Provides Recce Clinical Pipeline Update Jun 08
Recce Pharmaceuticals Ltd Announces Positive Results of Lead Compound RECCE® 327 May 29
Recce Pharmaceuticals Ltd Announces Further Results for its Synthetic Anti-Infective R327 May 20
Recce Pharmaceuticals Ltd Announces Positive Data on RECCE 327 Against All Six ESKAPE Pathogens May 05
Recce Pharmaceuticals Ltd Announces Lead Compound Recce 327 Added to the Pew Charitable Trusts' Annual List of Non-Traditional Products Mar 15
Recce Pharmaceuticals Ltd Formalizes Fiona Stanley Hospital Phase I/Ii Clinical Trial Agreement Feb 17
Recce Pharmaceuticals Ltd Announces Encouraging Results from Anti-viral Screening Program at The Doherty Institute Evaluating RECCE® 327 Against SARS-CoV-2 Feb 14
Recce Pharmaceuticals Ltd Announces Positive Intranasal Animal Data against SARS-CoV-2 in International Study Dec 25
Recce Pharmaceuticals Ltd Announces Encouraging Preliminary Results from Antiviral Screening Program At the Doherty Institute Evaluating RECCE® 327 Against SARS-CoV-2 Nov 12
Recce Pharmaceuticals Ltd Receives Human Research Ethics Committee Approval to Start a Phase I/Ii Clinical Trial of its Broad-Spectrum Antibiotic Recce® 327 on Patients with Infected Burn Wounds Oct 17
New 90-day low: €0.63 Oct 16 Recce Pharmaceuticals Ltd announced that it has received AUD 27.95 million in funding
Recce Pharmaceuticals Ltd announced that it expects to receive AUD 27.95 million in funding Sep 24
New 90-day high - €0.91 Sep 01
Recce Pharmaceuticals Ltd Appoints James Graham as CEO Aug 29 Shareholder Returns R9Q DE Pharmaceuticals DE Market 7D -4.8% -5.2% 0.5% 1Y -16.9% -10.6% 15.3%
See full shareholder returns
Return vs Market: R9Q underperformed the German Market which returned 13.7% over the past year.
Price Volatility Is R9Q's price volatile compared to industry and market? R9Q volatility R9Q Average Weekly Movement 7.5% Pharmaceuticals Industry Average Movement 5.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: R9Q's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: R9Q's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. Its lead candidate is RECCE 327 (R327) for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. The company also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use.
Show more Recce Pharmaceuticals Ltd Fundamentals Summary How do Recce Pharmaceuticals's earnings and revenue compare to its market cap? R9Q fundamental statistics Market cap €61.04m Earnings (TTM ) -€10.69m Revenue (TTM ) €3.04m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) R9Q income statement (TTM ) Revenue AU$5.03m Cost of Revenue AU$7.22m Gross Profit -AU$2.19m Other Expenses AU$15.47m Earnings -AU$17.66m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.076 Gross Margin -43.52% Net Profit Margin -351.24% Debt/Equity Ratio -101.7%
How did R9Q perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/06 10:40 End of Day Share Price 2025/02/06 00:00 Earnings 2024/06/30 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Recce Pharmaceuticals Ltd is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Pooya Hemami Edison Investment Research Chris Kallos MST Financial Services Pty Limited
